REGENXBIO (RGNX)
(Delayed Data from NSDQ)
$12.21 USD
+0.57 (4.90%)
Updated Jun 18, 2024 04:00 PM ET
After-Market: $12.19 -0.02 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
REGENXBIO Inc. [RGNX]
Reports for Purchase
Showing records 41 - 60 ( 65 total )
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Additional Ph1/2/3 CAMPSIITE Results for RGX-121/MPS II at SSIEM
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Q2: RGX-121/MPS II Ph1/2 Expands Into Ph1/2/3; Eyes on SCS Data Later This Yr
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Enrollment Complete in Cohort 5 of AAVIATE, Additional SCS Data Later This Yr
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Q1: Focus on RGX-314 in H2:22; Start to DMD Delayed; cGMP Facility Goes Live
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Internal Manufacturing Brings REGENXBIO Closer to Achieving 5x25 Strategy
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY21: 5x25 Strategy Led by RGX-314 Sets Opportunities for Value-Creation
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Angio 2022: Keeping Safety First While Advancing Towards Extended Duration
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
First-Look at RGX-111/MPS I & Additional Data for RGX-121/MPS II at WORLD
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Angiogenesis 2022 Preview: Updates from Ph2 ALTITUDE & AAVIATE for SCS-RGX-314
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
WORLDSymposium Preview: Data from Ph1/2 Trials of RGX-111 & RGX-121
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Ph3 ASCENT Study for Subretinal RGX-314/wAMD Initiated,BLA Targeted for 2024
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
IND Cleared for RGX-202/DMD, Phase 1/2 Trial Expected in H1:22
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A